I would agree, all these Bio-Investor conferences all over the world....Paris, Amersterdam, San Diego, NYC, enough.  If its a scientific meeting where people who are key to the decision to eventually perscribe 208 if its approved, okay. 

I still think the HL Eastern involvement is both a blessing and a curse....the share structure is so convoluted I don't see a BP player coming in and looking to acquire either Apabetalone by itself or the entire company.